At the Society of Nuclear Medicine and Molecular Imaging conference, Phillip Kuo, MD, PhD, FACR, professor at the College of Medicine – Tucson, discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals and new phase 3 study data.